Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$2.87
EPS est.
$2.41
EPS surprise
+19.09%
1-day move
+1.92%
DaVita's strong EPS performance, exceeding expectations by over 19%, contributed to a positive stock reaction, with shares rising by 1.92%. However, the lack of revenue data and management commentary leaves some uncertainty about the overall performance and future outlook. Investors may be encouraged by the earnings beat but will be looking for more information in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.87 | $2.33 | +19.09% |
| Revenue | N/A | $3.4B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
DaVita Inc. is a leading provider of kidney care services in the healthcare sector, focusing on dialysis and related services for patients with chronic kidney disease. With a market cap of $10 billion, DaVita plays a crucial role in managing a significant health issue, making it an important player in the healthcare services industry.
Last quarter
In Q4-2025, DaVita reported an EPS of $3.40, surpassing estimates by 5.07%. The stock reacted positively, gaining 1.69% the following day.
Management promises and guidance
EPS beat streak
3Q
EPS beat rate
75%
Avg EPS surprise
+2.47%
Avg 1-day reaction
+0.47%
Analysts expect DaVita to report solid earnings this quarter, with a consensus EPS of $2.33 and revenue of $3.4 billion. Investors will be keen to see if the company can maintain its growth trajectory amidst industry challenges.
Bull case
If DaVita beats EPS estimates and shows strong revenue growth, it could signal robust demand for its services, leading to a positive stock reaction.
Bear case
Conversely, if the company misses earnings expectations or shows signs of declining patient volumes, it could raise concerns about its future performance and negatively impact the stock.
Key metrics to watch
EPS
$2.33Earnings per share is a key indicator of profitability and will show how well DaVita is managing costs and revenues.
Revenue
$3.4BTotal revenue gives insight into the company's growth and demand for its services, which is vital for assessing its market position.
The print will turn on these.
Q1
Will DaVita's EPS exceed the consensus estimate of $2.33?
A beat on EPS would reinforce confidence in the company's profitability and operational efficiency.
Q2
How does DaVita plan to address any potential declines in patient volumes?
Understanding management's strategy for maintaining patient engagement is crucial for future revenue growth.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate DaVita's ability to maintain patient volumes due to its strong operational efficiencies and patient care strategies.
Supporting evidence
DaVita has a history of beating EPS estimates, with a 75% success rate over the last eight quarters.
The options market is pricing a significant move, indicating that investors expect volatility which could favor a positive surprise.
Key risk
If DaVita's patient volumes show unexpected growth, it could significantly alter the earnings outlook.
Pre-commit to what would confirm each case.
The upcoming earnings report is critical as it will reveal whether DaVita can sustain its growth amidst industry pressures.
Bull confirmed if
An EPS above $2.33 with revenue exceeding $3.4 billion would confirm the bull case.
Bear confirmed if
An EPS below $2.22 or revenue below $3.3 billion would confirm the bear case.
What the market is pricing for the move.
Implied Move
±11.04%
Historical Avg
±1.7%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±10.5% while DVA has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
27.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
48.38%
of float
Insider
46.91%
of float
Holders
860
institutions
Top Holders· as of Jun 2026
Berkshire Hathaway, Inc
28,880,209 sh · $5.1B
45.27%
-4.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If DaVita beats expectations, history suggests a positive stock reaction, averaging a +1.46% move.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future guidance.
Miss
A miss on earnings could lead to a decline, with history suggesting an average drop of -0.78%.
The lines on the call that would change the story.
Blackrock Inc.
2,460,987 sh · $435.1M
3.86%
-11.1%
Vanguard Capital Management LLC
2,101,425 sh · $371.5M
3.29%
-3.6%
Morgan Stanley
1,601,710 sh · $283.2M
2.51%
-3.9%
Vanguard Portfolio Management LLC
1,377,914 sh · $243.6M
2.16%
-6.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.